Mark Sabag, Executive Vice President of International Markets Commercial at Teva Pharmaceutical Industries Ltd. (NYSE:TEVA), recently sold a substantial block of the company's ordinary shares. The ...
With the settlement, Teva will not market the Auvelity generic until September 30, 2038, Axsome said in a Monday press ...
Zacks.com on MSN3d
Axsome Stock Surges 20% on Auvelity Patent Settlement With TevaShares of Axsome Therapeutics AXSM jumped 20.2% on Monday after the company announced that it has entered into a settlement ...
Shares in the brain drug developer rose by more than 20% Monday on news of the deal, which will forestall Teva's generic copy ...
Axsome Therapeutics, Inc. (NASDAQ:AXSM) signed a settlement agreement with Teva Pharmaceuticals Inc (NYSE:TEVA). The ...
CEO Richard Francis reflects on Teva’s return to growth during his tenure, and what’s next for the drugmaker in its quest to ...
Shares in biopharmaceutical group Axsome Therapeutics (AXSM) surged 23% today after it said it had settled a legal dispute ...
Pyridostigmine bromide extended-release tablets: Alvogen and Rising Pharmaceuticals have both reported shortages of pyridostigmine bromide 180-milligram, extended-release tablets. Rising estimated ...
Despite the recent launch of congenital adrenal hyperplasia (CAH) drug Crenessity, Neurocrine Biosciences' disappointing ...
Teva Pharmaceuticals Industries Ltd (NYSE: TEVA) is the world's largest generic drug maker, with over 500 generic and biosimilar treatments in its broad portfolio. The medical sector giant also ...
Shares of Axsome Therapeutics ( AXSM -0.49%) are up on Tuesday. The company's stock gained 4.1% as of 10:20 a.m. ET, but was ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback